Comparison
Abeta Amyloidosis Arctic Type C2751494 vs 17p11 2 Microduplication Syndrome C2931246
Clinical comparison between Abeta Amyloidosis Arctic Type and 17p11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
Abeta Amyloidosis Arctic Type C2751494
Hereditary amyloidosis from APP gene mutation causing amyloid buildup in brain blood vessels. Runs in families. Managed symptomatically.
17p11 2 Microduplication Syndrome C2931246
A chromosomal condition involving duplication on chromosome 17, related to Potocki-Lupski syndrome. Features often include developmental delays, learning challenges, and distinctive facial features.
6 comparison axes
Onset
Abeta Amyloidosis Arctic Type C2751494
50-65
17p11 2 Microduplication Syndrome C2931246
0-null
Onset patterns differ
Severity
Abeta Amyloidosis Arctic Type C2751494
severe
17p11 2 Microduplication Syndrome C2931246
moderate
Different severity levels
Chronic
Abeta Amyloidosis Arctic Type C2751494
Chronic
17p11 2 Microduplication Syndrome C2931246
Chronic
Differing course
Communicable
Abeta Amyloidosis Arctic Type C2751494
No
17p11 2 Microduplication Syndrome C2931246
No
Different transmission
Body System
Abeta Amyloidosis Arctic Type C2751494
neurologic
17p11 2 Microduplication Syndrome C2931246
congenital
Same/different system
Category
Abeta Amyloidosis Arctic Type C2751494
rare-disease
17p11 2 Microduplication Syndrome C2931246
genetic
Different category
Bottom line
abeta-amyloidosis-arctic-type-C2751494 and 17p11-2-microduplication-syndrome-C2931246 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abeta Amyloidosis Arctic Type C2751494 | 17p11 2 Microduplication Syndrome C2931246 | Discriminating power |
|---|---|---|---|
| Age at recognition | Typically recognized in adulthood, reported around ages 50–65. | Usually evident from infancy or childhood. | High |
| Main clinical pattern | Neurologic disease from amyloid in brain blood vessels; exact features vary. | Developmental delay, learning difficulty, and often distinctive facial features. | High |
| Inheritance clue | Familial APP-related amyloidosis; not contagious. | Chromosomal duplication related to Potocki-Lupski syndrome; not contagious. | Moderate |
When to favor each condition
Choose Abeta Amyloidosis Arctic Type C2751494 when
Adult-onset familial neurologic disease
The supplied onset and neurologic amyloid description fit this side.
Moderate
Suspected APP-related cerebral amyloid angiopathy
Source links the condition to an APP mutation and vascular amyloid.
Moderate
No congenital developmental phenotype
Absence of early developmental features makes the chromosomal syndrome less likely.
Low
Choose 17p11 2 Microduplication Syndrome C2931246 when
Infant or child with developmental delay
Early onset and developmental features match the supplied description.
Moderate
Learning difficulties with distinctive facial features
These are the stated characteristic findings.
Moderate
Suspected 17p11.2 duplication
Chromosomal testing is the relevant diagnostic pathway.
High
How key tests differ
| Test | Abeta Amyloidosis Arctic Type C2751494 | 17p11 2 Microduplication Syndrome C2931246 | Interpretation |
|---|---|---|---|
| APP gene testing | May identify the familial APP mutation when clinically suspected. | Not the primary test for a chromosomal microduplication. | A positive result supports the amyloidosis diagnosis; absence does not exclude all amyloid disease. |
| Chromosomal microarray | Not expected to establish Arctic-type amyloidosis. | Can detect duplication at 17p11.2. | Confirms the chromosomal condition when the duplication is found. |
| Brain imaging | May be used to assess vascular or neurologic complications; findings are not definitive alone. | Not diagnostic of the duplication, although developmental evaluation may prompt imaging. | Imaging supports assessment but genetic testing distinguishes the conditions. |
Prognosis comparison
Abeta Amyloidosis Arctic Type C2751494
- Outcome
- Described as severe and chronic, with symptomatic management; exact survival is not established here.
- Factors
- Age at onset, neurologic complications, and family genotype may influence course.
17p11 2 Microduplication Syndrome C2931246
- Outcome
- Described as moderate and chronic, often with lasting developmental and learning needs.
- Factors
- Degree of developmental delay, learning support, and associated congenital findings.
Time frame: Left is typically adult-onset; right begins in early life. Long-term outcomes vary.
Prognosis is not interchangeable and should be interpreted by the treating clinician.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic decline | Possible progressive neurologic disease; course is not fully established here. Cognitive or learning impairment may persist, generally developmental rather than adult-onset vascular. Severity and trajectory require individualized assessment. |
| Vascular brain injury | Amyloid in brain vessels may predispose to vascular complications. Not described as a vascular amyloid disorder. Do not infer stroke risk or exact outcomes from these data. |
| Developmental disability | Not the defining presentation in the supplied source. Developmental delay and learning challenges are central features. Support needs depend on individual function. |
Patient education highlights
- HighDifferent conditions
One is adult-onset brain-vessel amyloid disease; the other is a congenital chromosomal syndrome.
- HighGenetic counseling
Families should discuss inheritance, testing of relatives, and reproductive options with a genetics clinician.
- MediumSymptom-based care
Management is individualized. No treatment dose or definitive outcome should be assumed from this comparison.